Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Acute Myeloid Leukemia
92%
Childhood Acute Lymphoblastic Leukemia
83%
Pediatric Leukemia
78%
Acute Lymphoblastic Leukemia
47%
Chronic Myeloid Leukemia
38%
Minimal Residual Disease
38%
Pediatric Hematology
31%
Pediatric Oncology
30%
Imatinib
26%
Stem Cell Transplantation
19%
Event-free Survival
19%
International Registry
19%
KMT2A
19%
Overall Survival
19%
Leukemia
18%
Induction Therapy
17%
Confidence Interval
17%
Flow Cytometry
17%
Leukemia Patients
17%
Working Diagnosis
17%
Childhood Chronic Myeloid Leukemia
15%
5-year Survival
14%
Relapse Risk
14%
6-mercaptopurine (6-MP)
14%
Pediatric
13%
Nordic Countries
13%
Prognostic Impact
13%
Quantitative PCR
12%
Peripheral Blood
12%
Hyperleukocytosis
12%
Prognostic Factors
11%
Hematopoietic Stem Cell Transplantation
11%
Childhood Cancer
11%
Interprofessional Education
11%
High Risk
11%
High-dose Methotrexate (HD-MTX)
11%
Maintenance Therapy
10%
Polymorphism
10%
Hazard Ratio
10%
Etoposide
9%
Fusion Transcript
9%
Pediatric Patients
9%
Chemotherapy
9%
Residual Disease
9%
Disease Monitoring
9%
Healthcare Professionals
9%
White Blood Cell Count
9%
Chronic Phase
9%
Progression-free Survival
8%
Risk Stratification
8%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Pediatric Acute Myeloid Leukemia
61%
Acute Lymphoblastic Leukemia
57%
Minimal Residual Disease
43%
Chronic Myelogenous Leukemia
42%
Pediatrics
31%
Pediatric Hematology
31%
Overall Survival
29%
Pediatric Oncology
28%
Imatinib
26%
Adolescent
23%
Flow Cytometry
22%
Infection
22%
Stem Cell Therapy
17%
Event Free Survival
16%
Leukocyte
15%
Hematopoietic Stem Cell Transplantation
15%
Acute Myelogenous Leukemia
14%
Leukemia in Children
14%
Prognostic Factor
13%
Leukemia
12%
Disease
12%
Etoposide
11%
Pediatrics Patient
9%
Cell Count
9%
Hemolytic Anemia
9%
Drug Megadose
9%
Childhood Cancer
9%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Cytarabine
8%
Hazard Ratio
8%
Survival Rate
8%
Mitoxantrone
8%
Interprofessional Education
8%
High Risk Population
7%
Risk Stratification
7%
Mercaptopurine
7%
Methotrexate
7%
Progression Free Survival
7%
Liposomal Daunorubicin
7%
Body Mass Index
7%
Supportive Care
6%
Anemia
6%
Malignant Neoplasm
6%
Long Term Survival
6%
Real-Time Polymerase Chain Reaction
6%
Spontaneous Remission
6%
Obesity
6%
Missense Mutation
5%
Idarubicin
5%
